<DOC>
	<DOCNO>NCT00301912</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , busulfan fludarabine , work different way stop growth cancer cell , either kill cell stop divide . Giving chemotherapy peripheral stem cell bone marrow transplant may allow chemotherapy give cancer cell kill . Sometimes transplanted cell donor make immune response body 's normal cell . Tacrolimus methotrexate may stop happen . PURPOSE : This phase II trial study well give busulfan together fludarabine donor stem cell transplant work treat patient hematologic cancer .</brief_summary>
	<brief_title>Busulfan Fludarabine Before Donor Stem Cell Transplant Treating Patients With Hematologic Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine safety , term treatment-related mortality 100 day post-transplantation , myeloablative preparative regimen comprise busulfan fludarabine graft-vs-host disease ( GVHD ) prophylaxis comprise tacrolimus methotrexate patient hematopoietic disorder undergo match unrelated donor stem cell transplantation . - Determine efficacy , term overall survival 1-year post-transplantation , patient treat regimen . Secondary - Determine organ toxicity patient treated regimen . - Determine neutrophil platelet recovery patient treat regimen . - Determine incidence severity acute chronic GVHD patient treat regimen . OUTLINE : - Myeloablative preparative regimen : Patients receive busulfan IV 2 hour every 6 hour day -7 -4 fludarabine IV 30 minute day -7 -3 . - Allogeneic stem cell transplantation : Patients undergo allogeneic peripheral blood stem cell bone marrow transplantation day 0 . Patients also receive filgrastim ( G-CSF ) subcutaneously daily begin day 7 continue blood count recover . - Graft-vs-host disease prophylaxis : Patients receive tacrolimus IV continuously begin day -2 continue discharged hospital ( may convert oral dosing administer twice daily tolerate ) methotrexate IV 15-30 minute day 1 , 3 , 6 , 11 . After completion study therapy , patient follow periodically . PROJECTED ACCRUAL : A total 36 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis 1 follow hematopoietic disorder : Chronic myelogenous leukemia ( CML ) , meet 1 follow criterion : Chronic phase disease fail imatinib mesylate therapy Progressive disease OR fail achieve major cytogenetic response 1 year initiation therapy Accelerated phase disease , meet 1 follow criterion : Failed achieve complete cytogenetic remission 1 year initiation therapy Failed achieve cytogenetic response 3 6 month therapy Progressive disease , demonstrate worsen cytogenetic response 2 consecutive analysis separate 4 week Blast crisis &lt; 10 % blast bone marrow within 6 week transplantation Acute myeloid leukemia ( AML ) , meet 1 follow criterion : In second great remission In first remission poor prognosis cytogenetics [ 5 , 5q , 7 , 7q ≥ 2 cytogenetic abnormality , ( 6,9 ) , ( 9,11 ) , Philadelphia chromosome ] In hematologic remission persistent cytogenetic abnormality Primary refractory AML &lt; 10 % blast bone marrow within 6 week transplantation Myelodysplasia &lt; 20 % blast bone marrow within 6 week transplantation meet 1 follow criterion : Advanced disease ( International Prognostic Scoring System [ IPSS ] score intermediate1 , intermediate2 , high risk ) Myelodysplastic syndrome ( MDS ) progression AML Treatmentrelated AML Acute lymphocytic leukemia ( ALL ) , meet 1 follow criterion : In second great remission In first remission highrisk cytogenetics [ Philadelphia chromosome ; ( 4,11 ) ; 7 ] Primary refractory ALL &lt; 10 % blast bone marrow Severe aplastic anemia fail immunosuppressive therapy NonHodgkin 's lymphoma , meet 1 follow criterion : In second great remission Relapsed disease patient eligible autologous stem cell transplantation Lymphoproliferative disease ( e.g. , chronic lymphocytic leukemia Waldenstrom 's macroglobulinemia ) , meet 1 follow criterion : In second great remission Relapsed disease patient eligible autologous stem cell transplantation Multiple myeloma , meet 1 follow criterion : Stage II III disease first great relapse Refractory disease Newly diagnose disease chromosome 13 abnormality Advanced myeloproliferative disease , meet 1 follow criterion : Myelofibrosis require &gt; 2 unit pack red blood cell month Essential thrombocythemia polycythemia rubra vera progress AML Failed prior AML therapy No active , uncontrolled CNS leukemia Not eligible autologous miniallogeneic transplantation No fully match singleantigen mismatch sibling donor available HLAmatched unrelated donor available HLA type HLAA , B , C , DRB1 and/or DQB1 highresolution technique For patient without HLA identical donor , mismatch DQ ( i.e. , 8/8 match ) 1 additional mismatch allele level HLAA , B , C , DRB1 ( i.e. , 7/8 molecular match ) allow PATIENT CHARACTERISTICS : ECOG performance status 02 Creatinine &lt; 2.0 mg/dL Pulmonary diffusing capacity &gt; 40 % predict Cardiac ejection fraction &gt; 40 % MUGA echocardiography No active liver disease Bilirubin ≤ 2.0 mg/dL Alkaline phosphatase &lt; 3 time upper limit normal ( ULN ) AST &lt; 3 time ULN Hepatitis C active hepatitis B ( HBV ) allow provide liver biopsy perform ≤ grade 2 inflammation present Patients active HBV viral replication must receive antiviral therapy HIV negative No ongoing active infection Not pregnant nursing Negative pregnancy test PRIOR CONCURRENT THERAPY : See Disease Characteristics More 3 week since prior chemotherapy except hydroxyurea imatinib mesylate More 3 month since prior interferon</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
	<keyword>adult acute myeloid leukemia remission</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>atypical chronic myeloid leukemia</keyword>
	<keyword>myelodysplastic/myeloproliferative disease , unclassifiable</keyword>
	<keyword>adult acute lymphoblastic leukemia remission</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>anemia</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>stage III chronic lymphocytic leukemia</keyword>
	<keyword>stage IV chronic lymphocytic leukemia</keyword>
	<keyword>Waldenstrom macroglobulinemia</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>polycythemia vera</keyword>
	<keyword>essential thrombocythemia</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>chronic eosinophilic leukemia</keyword>
	<keyword>chronic idiopathic myelofibrosis</keyword>
	<keyword>chronic myelomonocytic leukemia</keyword>
	<keyword>chronic neutrophilic leukemia</keyword>
	<keyword>noncontiguous stage II adult Burkitt lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse mixed cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse small cleave cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult immunoblastic large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult lymphoblastic lymphoma</keyword>
	<keyword>noncontiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II mantle cell lymphoma</keyword>
	<keyword>noncontiguous stage II marginal zone lymphoma</keyword>
	<keyword>noncontiguous stage II small lymphocytic lymphoma</keyword>
	<keyword>stage III adult Burkitt lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage III adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage III adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage III adult lymphoblastic lymphoma</keyword>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage III marginal zone lymphoma</keyword>
	<keyword>stage III small lymphocytic lymphoma</keyword>
	<keyword>stage IV adult Burkitt lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV adult lymphoblastic lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>stage I multiple myeloma</keyword>
	<keyword>childhood myelodysplastic syndrome</keyword>
</DOC>